ABBV
AbbVie Inc.
AbbVie is a large-cap pharmaceutical company whose immunology and oncology franchises are highly exposed to Medicare drug-price negotiation and FDA/patent policy.
Govt Dependence
82/100
Regulatory Density
90/100
Lobbying Intensity
88/100
Political Signal
HIGH
BusinessWhat ABBV does
AbbVie develops and markets branded pharmaceuticals across immunology (Skyrizi, Rinvoq, legacy Humira), oncology, neuroscience, aesthetics (Botox) and eye care. Revenue is driven by patent-protected biologics and small molecules, with heavy Medicare and commercial-payer exposure.
12 months past · 3 months futureABBV activity timeline
Congress
buy
sell
Insider · Form 4
open-market buy
Hedge fund · 13F
opened
+ added
− trimmed
closed
holds
Bills
past action (this ticker)
upcoming markup (sector)
★ carveout (this ticker)
167 trading days ·
23 congressional trades shown
·
0 insider buys
·
8 13F filings
·
1 past bill actions
·
3 upcoming markups
Executive Branch ConflictsABBV held by Trump-administration officials
1 cabinet/senior official reported ABBV positions in OGE Form 278 disclosures across 36 filings.
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
ABBVIE INC
pharma
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
ABBVIE INC
Donald J. Trump
President · White House
AbbVie Inc
pharma
Donald J. Trump
President · White House
ABBVIE INC
Lifetime Government AwardsABBV federal contracts
ABBV doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding ABBV
$39.59B
Total ABBV held by tracked 13F funds
5
Funds with ABBV positions
Two Sigma Investments
$38.80B
+56%
4 overlap
2026-03-31
Citadel Advisors
$465M
-32%
11 overlap
2025-12-31
Millennium Management
$169M
-63%
2025-12-31
D.E. Shaw & Co.
$153M
+12%
11 overlap
2025-12-31
Bridgewater Associates
$3M
-95%
11 overlap
2025-12-31
Politicians Trading ABBVMembers of Congress with recent ABBV positions
13 politicians traded ABBV across 88 disclosed transactions totaling $1.2M (last 730 days).
Greed score = composite of trade frequency, volume & recency across the politician's entire history (not just ABBV). 0-30 LOW · 30-60 MID · 60+ HIGH.
Ro Khanna
20 buys
11 sells
$444K
2026-05-01
LOW · 0
Jefferson Shreve
2 buys
2 sells
$300K
2025-04-17
LOW · 0
Lisa C. McClain
6 buys
6 sells
$96K
2025-10-31
LOW · 0
Josh Gottheimer
6 buys
3 sells
$72K
2026-05-05
LOW · 1
Robert P. Bresnahan
4 buys
2 sells
$48K
2025-05-15
LOW · 0
Ritchie Torres
2 buys
2 sells
$32K
2025-07-11
LOW · 0
Julie Johnson
4 sells
$32K
2025-12-18
LOW · 15
Julia Letlow
2 buys
2 sells
$32K
2025-12-08
LOW · 1
Jared Moskowitz
4 buys
$32K
2025-04-07
LOW · 0
John Boozman
4 sells
$32K
2025-08-22
MID · 47
John James
2 sells
$16K
2024-09-04
LOW · 0
Dwight Evans
2 sells
$16K
2025-04-03
LOW · 0
Virginia Foxx
2 buys
$16K
2024-12-06
LOW · 1
Congressional TradesWho in Congress is trading ABBV
2026-05-01
Ro Khanna
Purchase
$15,001 - $50,000
2026-05-05
Josh Gottheimer
Sale
$1,001 - $15,000
2026-01-29
Ro Khanna
Sale
$15,001 - $50,000
2026-01-23
Ro Khanna
Purchase
$1,001 - $15,000
2025-12-18
Julie Johnson
Sale
$1,001 - $15,000
2025-04-28
Julia Letlow
Purchase
$1,001 - $15,000
260d late
2025-01-24
Julia Letlow
Sale
$1,001 - $15,000
354d late
2025-12-08
Julia Letlow
Sale
$1,001 - $15,000
2024-10-23
Julia Letlow
Purchase
$1,001 - $15,000
447d late
2025-11-13
Julie Johnson
Sale
$1,001 - $15,000
2025-10-30
Lisa C. McClain
Purchase
$1,001 - $15,000
2025-10-30
Lisa C. McClain
sale
$1,001 - $15,000
30+ trades on file · most recent 2026-06-11
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
Stock awards & option exercises
100
stock awards · $213.0M market value
3
option exercises · $3.9M
2026-05-08
Hart Brett J
Other
AWARD
1,118 sh
$225K
2026-05-08
MEYER MELODY B
Other
AWARD
1,118 sh
$225K
2026-05-08
RAPP EDWARD J
Other
AWARD
1,118 sh
$225K
2026-05-08
Quaggin Susan E
Other
AWARD
1,118 sh
$225K
2026-05-08
AUSTIN ROXANNE S
Other
AWARD
1,118 sh
$225K
2026-05-08
WADDELL FREDERICK H
Other
AWARD
1,118 sh
$225K
2026-05-08
FALK THOMAS J
Other
AWARD
1,118 sh
$225K
2026-05-08
Roberts Rebecca B
Other
AWARD
1,118 sh
$225K
For ABBV, executives receive stock primarily as compensation rather than via open-market purchases — typical for established large-cap firms.
Bills Affecting ABBVLive legislation impacting this stock
HR.1860 · 119th
Women Veterans Cancer Care Coordination Act
HR.1875 · 119th
Medicaid Provider Screening Accountability Act
HR.1867 · 119th
To amend title XVIII of the Social Security Act to remove in-person requirements under Medicare for mental health services furnish
HR.1843 · 119th
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
HRES.185 · 119th
Recognizing the need of Congress to prevent, address, and treat obesity as a disease in the United States on this World Obesity Da
HRES.182 · 119th
Expressing support for the designation of March 3, 2025, as "National Triple-Negative Breast Cancer Day".
HR.1806 · 119th
Triple-Negative Breast Cancer Research and Education Act of 2025
S.786 · 119th
Public Health Funding Restoration Act
S.763 · 119th
Telehealth Expansion Act of 2025
SRES.90 · 118th
A resolution recognizing the significance of endometriosis as an unmet chronic disease for women and designating March 2023 as "En
Political ProfileWhere ABBV sits in Washington
bipartisan
Large-cap pharma stocks move materially on Medicare price-negotiation lists, IRA implementation, and FDA/patent policy; AbbVie's Humira/Skyrizi exposure makes it drug-pricing sensitive.
Regulatory ExposureThreats & opportunities
Regulatory threats
- Medicare drug price negotiation expansion
- patent thicket / biosimilar competition reform
- FTC/FDA scrutiny of patent listings
- IRA compulsory-licensing style proposals
Regulatory opportunities
- FDA approval accelerations for Skyrizi/Rinvoq
- favorable IP/tax treatment (HR.1911)
- biosimilar market delays extending exclusivity
Capitol Hill AlliesChampions & critics
Congressional champions
- No specific congressional champions identified.
Congressional critics
- Sen. Warren (D-MA)
- Sen. Sanders (I-VT)
LobbyingWho's hired to advocate for ABBV
PhRMABiotechnology Innovation Organization (BIO)U.S. Chamber of Commerce
Member intelligence layer
Live signals + predictions for ABBV — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades ABBV
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord
Frequently AskedAbout ABBV & political exposure
Does AbbVie Inc. (ABBV) hold federal contracts?
No direct prime contracts reported in USASpending.gov for AbbVie Inc.. Companies in the semiconductor and AI hardware sectors often sell to the federal government via prime contractors and cloud resellers (Microsoft Azure, AWS, Lockheed Martin systems integration) rather than as direct primes.
Which Trump cabinet officials own ABBV stock?
1 Trump cabinet members or senior White House staff have disclosed holdings in ABBV on their OGE 278 financial disclosures, including Donald J. Trump. See the Cabinet Conflicts panel for details.
Has Congress traded ABBV stock?
480 congressional trades by 55 unique members of Congress, most recently on 2026-05-05. See the Congressional Trading panel for politician-by-politician breakdown.
What is ABBV political risk profile?
Government dependence: 82/100. Lobbying intensity: 88/100. Political signal: high. Donor party split: bipartisan.
How does GovGreed track ABBV political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. ABBV data is updated daily from these official federal sources.